Thursday, August 21, 2025

Creating liberating content

Market analysts maintain an optimistic near-term outlook, citing government policy

Top stocks to buy (AI image) Top stock market recommendations:

Mumbai: Uncertainty over US President Donald Trump’s tariffs and external

Related News

Gold prices expected to rise (AI-image) Gold prices may scale another record by the end of this year, with Comex futures projected to hit $3,600 per ounce, according to Ventura

Market analysts maintain an optimistic near-term outlook, citing government policy initiatives and increased consumption as key drivers. (AI image) Stock market today: Nifty50 and BSE Sensex, the Indian equity benchmark

Top stocks to buy (AI image) Top stock market recommendations: According to Aakash K Hindocha, Deputy Vice President – WM Research, Nuvama Professional Clients Group, Godawari Power and Ispat Limited,

Mumbai: Uncertainty over US President Donald Trump’s tariffs and external demand clouded the Monetary Policy Committee’s assessment of the future path of growth and inflation, prompting it to hold back

MUMBAI: Indian cricket’s latest blue-eyed boy, Shubman Gill, is the new favourite with brands. His stellar performance in the India-England Test series, both as captain and batsman, had already bolstered

CHENNAI: A little over a year after UltraTech Cement acquired India Cements, billionaire industrialist Kumar Mangalam Birla’s building materials flagship is set to sell Rs 740 crore worth of India

Trending News

JSW Cement, the building materials arm of Sajjan Jindal-led JSW Group, has reduced the size of its upcoming initial public offering (IPO) to Rs 3,600 crore and will open the

The agricultural Gross Value Added (GVA) growth is expected to moderate to 4.5% in the first quarter of FY26, down from 5.4% in the preceding quarter, according to a report

Foreign portfolio investors (FPIs) turned net sellers in the Indian equity market in July, pulling out Rs 17,741 crore amid rising global trade tensions. According to data from NSDL, this

Avenue Capital Group-backed Asset Reconstruction Company (India) Ltd (ARCIL) has filed its draft red herring prospectus (DRHP) with markets regulator Sebi on Friday to raise funds through an initial public

Russia-backed Nayara Energy looks at India’s state-run oil companies to offload petrol, diesel exports Nayara Energy has approached Indian state-run oil marketing companies (OMCs) to offload its export volumes of

US President Donald Trump on Saturday claimed that he had “heard” reports of India halting Russian oil imports, hailing it as a “good step”. “I understand that India is no

Novo Nordisk expands discounted Wegovy to cash-paying U.S. customers

Word Count: 309 | Estimated Reading Time: 2 minutes


Jakub Porzycki | Nurphoto | Getty Images

Novo Nordisk said on Monday all eligible cash-paying customers in the United States can buy its weight-loss drug Wegovy at a discounted price of $499 per month at their local pharmacy.

U.S.-listed shares of Novo fell more than 2.5% to $74.92 in premarket trading. Novo has also lost its spot as Europe’s largest company to German software firm SAP having underperformed the market in recent months.

The Danish drugmaker and rival Eli Lilly have begun offering their popular weight-loss drugs at discounted prices, as they grapple with shifts to the competitive dynamic of the highly lucrative obesity drug market.

Investors have been worried about growing competition with Lilly as well as disappointing data from its next-generation weight-loss candidate CagriSema, which Novo hopes will be a powerful successor to Wegovy.

Last month, Lilly cut the price for vials of its weight-loss drug Zepbound by $50 or more and expanded the range of doses sold online to try to stave off competition.

Compounding pharmacies have been selling hundreds of thousands of doses of copies of Wegovy while it was in shortage. The Food and Drug Administration has since asked them to cease making copies but will hold off on taking action until a federal court delivers its ruling in a lawsuit.

Wegovy can cost more than $1,000 per month for those who do not have health insurance coverage. The high costs had been widely criticized by former President Joe Biden and U.S. Senator Bernie Sanders, among others.

Until now, the drug was only available at the discounted price through its NovoCare Pharmacy program.

The expanded program will offer all dosage strengths of the drug to uninsured patients or eligible patients with commercial insurance who do not have coverage for obesity medicines.

This replaces Novo’s previous program through which it offered month’s supply of Wegovy for $650.



Source link

Sign In

Welcome ! Log into Your Account